THE US Food and Drug Administration (FDA) has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.
Vosevi is a fixed-dose, combination tablet containing two previously approved drugs -- sofosbuvir and velpatasvir -- and a new drug, voxilaprevir.
Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A.
The Vosevi combination product is not yet available in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jul 17